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HYPOTENSIVE DRUGS 
By G. E. MA WER 
B. Sc. 
Based on a Dissertation read before the Royal 
Medical Society on Friday, 23rd October 1959. 
The arterial blood pressure is controlled by the autonomic nervous system. 
Information about the level of the arterial pressure is obtained by the stretch 
receptors of the aortic arch and the carotid sinus. An increase in pressure 
is registered as an increase in sensory discharge frequency and vice-versa. 
The sensory impulses reach the medulla by the carotid sinus nerves, the 
cardia-aortic nerves and the vagi. The central nervous mechanisms are such 
that changes in the arterial pressure evoke compensatory changes in the 
dynamics of the circulation. A fall in carotid sinus pressure, for example, 
evokes peripheral arteriolar constriction. an increase in venous tone and an 
increase in heart rate. Generalised arteriolar constriction increases total peri-
pheral resistance. An increase in venous tone tends to increase the venous 
tilling pressure and the stroke volume of the heart. The combined increase 
in stroke volume and heart rate produces a rise in cardiac output, which, 
together with the increase in peripheral resistance, restores the origmal arterial 
pressure. 
The circulatory adjustments which regulate arterial blood pressure require 
a normally functioning sympathetic nervous system; peripheral arteriolar 
constriction is brought about by the release of noradrenaline from sympathetic 
nerve endings or by the release of adrenaline from the adrenal medulla; the 
same mechanisms are also responsible for the increase in venomotor tone and 
in part for the increase in heart rate. 
The patient with early essential hypertension has compensatory reflex 
mechanisms which function in the normal way. The difference between him 
and the normal man is in the actual level of arterial blood pressure. The 
"setting'' of these mechanisms has become altered so that the pressure level 
which they maintain is above the normal range. Immediately the pressure is 
lowered to a physiological level the homeostatic mechanisms act to restore 
the hypertensive state. Sustained lowering of the arterial pressure can, how-
ever, be obtained by the use of drugs which prevent the normal functioning 
of the homeostatic reflexes. The anatomical pathways for these reflexes can 
be interrupted at many points:-
I. Carotid sinus and aortic arch. 
2. Central nervous system. 
3. Sympathetic ganglia. 
4. Sympathetic post-ganglionic nerves. 
5. Peripheral adrenergic receptors. 
l. Drugs Acting on the Carotid Sinus and Aortic Arch 
Plants of the genus Veratrum contain alkaloids with characteristic 
properties. Selective extraction yields the mixture of alkaloids known as 
Vcriloid and further purification gives the pure crystalline alkaloids proto-
veratrine A and B. 
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The intravenous injection of protoveratrine is followed by a rapid fall 
in blood pressure. This is accompanied by bradycardia and persists for 
one to three hours. 
The veratrum alkaloids can be given orally and they have been used in 
the treatment of moderate hypertension and in pre-eclampsia. They suffer 
from several disadvantages, however. The duration of the effect is short 
and there is a low therapeutic ratio. The dose which lowers blood pressure 
is only slightly less than the dose which produces vomiting. 
The veratrum alkaloids produce a fall in blood pressure by actions on 
sensory receptors in the heart, lungs and carotid sinus. Probably the 
pressure receptors are sensitised so that a given sensory discharge frequency 
is produced by a lower arterial pressure. If this is the case, the veratrum 
alkaloids. can be described as "re-setting" the pressure regulating mechanisms 
so that they control the blood pressure at a lower level. Theoretically a 
drug which acts in this way is the ideal hypotensive agent; the pressure 
regulating mechanisms are not abolished, they are re-adjusted to a physio-
logical level. It is unfortunate that the veratrum alkaloids have such a short 
action and are so liable to produce undesirable side effects. 
2. Drugs which act on the Central Nervous System 
The normal functioning of those parts of the central nervous system 
which regulate the circulation is modified by a large number of drugs. 
Normal sleep is associated with a fall in arterial blood pressure. This 
occurs in both normal and hypertensive people and when the sleep is drug-
induced. To this extent the hypnotics are hypotensive agents. 
The acute rises in arterial pressure associated with emotion or excite-
ment arc prevented or reduced by the sedatives and tranquillisers. 
During surgical anaesthesia the blood pressure is lowered; the total 
peripheral resistance is reduced by a direct effect on the arterioles and by 
a remote effect on the vasomotor centre. The force of myocardial systole 
is also reduced. Certain general anaesthetics, notably halothane, appear to 
block transmission in the autonomic ganglia. Slight increases in the con-
centration of halothane inhaled are often associated with abrupt falls in 
arterial blood pressure. 
The administration of a medium-acting barbiturate, for example sodium 
amytal. to a hypertensive patient often produces a marked fall in arterial 
blood pressure. 
3. Drugs which act on Sympathetic Ganglia 
Special interest is attached to this synapse because it is a point on the 
vasoconstrictor pathway which is vulnerable to specific blockade. 
Although ganglionic transmission is a continuous process. for convenience 
of description it may be divided into several stages: 
I. Saltatory conduction in the pre-ganglionic nerve fibre. 
2. Non-saltatory conduction in the non-myelinated terminal fibrils. 
3. Release of acetyl choline at the boutons terminaux. 
4. The crossing of the "synaptic gap" by acetyl choline. 
5. The adsorption of acetyl choline at the receptor sites on the post-
synaptic membrane. 
6. Depolarisation of the membrane and the initiation of a propagated 
action potential. 
Transmission may be blocked at each stage by the use of suitable 
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pharmacological agents. Stages 5 and 6 are interrupted by nicotine, the 
tetra·alkylammonium compounds, the methonium salts, mecamylamine and 
pempidine. Special interest is attached to this group because it includes 
the most speciuc ganglion blocking agents. 
Langley in his classical studies on the anatomy and physiology of the 
autonomic nervous system, made extensive use of nicotine. He was able to 
demonstrate the presence of peripheral synapses which were selectively 
blocked by nicotine. Low doses of nicotine stimulate sympathetic ganglia 
and provoke the release of adrenaline from the adrenal medulla. The drug 
has important actions on a large number of other sites and is not suitable 
for clinical ganglion blockade. 
Burn and Dale in 1914 showed that tetraethylammonium bromide 
closely resembled nicotine. The tetraethylammonium ion was shown to block 
ganglion transmission without preliminary stimulation. However, the latter 
suffered from several disadvantages; it had to be given by injection and the 
hypotensive effect was short. In addition the drug produced neuromuscular 
blockade. Nevertheless tetraethylammonium bromide was used in the 
emergency treatment of acute left ventricular failure secondary to hyper· 
tension and as a diagnostic tool to predict the response to sympathectomy. 
Barlow and Ing in Oxford, and Paton and Zaimis in London developed 
the methonium compounds, which consist of two quaternary ammonium 
groupings linked by a polymethylene chain. The pharmacological properties 
are determined by the length of this chain. The members of the series with 
5 or 6 methylene groups are very active as ganglion blocking drugs, but do 
not prevent neuromuscular transmission. 
The penta· and hexa-methylene compounds, pentamethonium, and hexa· 
methonium, were tested on hypertensive patients. They were very effective 
hypotensive agents but absorption from the alimentary tract was poor and 
unpredictable. The drugs were given parenterally and hypertensive patients 
were taught self·administration. 
A large number of structural analogues was prepared. Among these 
was pentolinium (Ansolysen) which is closely related to pentamethonium 
but better absorbed. In many cases it was possible to obtain adequate 
control of blood pressure with oral pentolinium. However quaternary 
ammonium salts as a group are absorbed slowly and to an incomplete extent. 
Further progress was not made until the advent of the "amine" ganglion 
blocking drugs, mecamylamine (lnversine) and pempidine, which are absorbed 
rapidly and almost completely after oral ingestion. 
Following absorption there are important differences in behaviour 
between the quaternary ammonium and the amine ganglion blocking drugs. 
Hexamethonium is confined to the extracellular fluid compartment and does 
not penetrate the blood·brain barrier. It is excreted by glomerular filtration 
and not reabsorbed by the renal tubules. The restricted distribution, the 
absence of binding to tissue protein and the rapid excretion combine to 
produce rapid removal of the drug. For this reason the degree of ganglion 
blockade produced by hexamethonium fluctuates relatively rapidly. 
The secondary amine mecamylamine is distributed throughout the body 
fluids. It is bound to the tissue proteins and tubular reabsorption in the 
kidney reduces the rate of excretion. Thus the degree of ganglion blockade 
produced by mccamylamine is more uniform than with hexamethonium. 
Mecamylamine penetrates the blood·brain barrier and some patients develop 
tremors. 
The difference between hexamethonium and mecamylamine are due to 
the differences in the state of the nitrogen atoms in the two molecules. The 
heavily charged quaternary ammonium cation is not able to penetrate cell 
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membranes. The substituted amines are readily absorbed by cells as the 
free bases. 
It is not possible to state which is the better of the two drugs mecamyl-
amine and pempidine at present. A clinical trial of these two drugs is 
being conducted in the Royal Infirmary, Edinburgh, using a "double blind" 
technique. 
The Cardiovascular Effects of Ganglion Blockade 
Ganglion blockade produces only a slight fall in the supine blood pressure 
of the normal subject. The fall is greater, however, in the hypertensive 
patient. This is probably due to the fall in total peripheral resistance which 
results from the interruption of the sympathetic vasoconstrictor pathway. 
A much greater fall in both diastolic and systolic pressures is obtained when 
the patient stands erect. This is due to haemodynamic changes which can 
no longer be corrected. 
With the assumption of the erect posture the hydrostatic pressure dis-
tending the veins of the abdomen and lower limbs is increased. In the 
absence of compensatory venoconstriction these veins dilate and accommo-
date a larger proportion of the total venous blood. The volume which 
remains in the great veins near the heart is therefore decreased. This is 
accompanied by a fall in venous filling pressure and in cardiac output. 
Reduced cardiac output and reduced peripheral resistance together produce 
a fall in arterial blood pressure. Normally this would evoke the compen-
satory reflex mechanisms described earlier, but ganglion blockade prevents 
this. 
When the degree of ganglion blockade is excessive the pressure may fall 
from hypertensive to hypotensive levels. This is commonly associated with 
symptoms of cerebral ischaemia, dizziness, "light-headedness" and fainting. 
Many physicians encourage their patients to take enough drug to produce 
symptoms of postural hypotension once or twice during the day. They are 
also advised to take advantage of the postural effect by sleeping with the 
head of the bed raised. 
The effects of ganglion blockade on peripheral blood flow vary from 
one tissue or organ to another: 
I. Skin. The sympathetic adrenergic innervation of skin vessels is 
constrictor. Ganglion blockade is usually associated with an increase 
in blood flow to the foot and to the hand. This is due largely to 
increased skin flow. 
2. Voluntary muscle. The sympathetic innervation of the arteries and 
arterioles of skeletal muscle is largely dilator. Forearm flow, which 
is chiefly muscle flow, is usually unchanged by ganglion blockade. 
3. Brain. The blood flow to the brain is under autonomous control; 
it remains almost constant in spite of wide variations in arterial blood 
pressure. In the healthy young adult cerebral ischaemia is only pro-
duced by severe postural hypotension, but the aged hypertensive is 
quite different. Hypertensive arteriolar sclerosis offers a high. 
relatively fixed resistance to blood flow. Ganglion blockade reduces 
arterial pressure and predisposes to thrombosis. ischaemia and 
infarction. 
4. Myocardium. Reduction in the aortic diastolic pressure has a two-
fold effect. The coronary blood flow may be reduced but so also 
is the work demanded from the myocardium. The effect on coronary 
ischaemia depends on which predominates. 
5. Kidney. The renal blood flow is never increased by ganglion 
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blockade. There is evidence that the reduction in renal blood flow 
produced by the fall in arterial pressure is temporary; adaptation 
may restore normal blood flow after a few hours. 
Carefully controlled treatment by ganglion blockade with regular attend-
ance at hypertensive clinics can be very successful. Some patients enjoy 
adequate control with the minimum of side effects. Others experience all 
the side effects at dose levels which are not adequate to control hypertension. 
The majority have one or two side effects. 
It may require a great deal of encouragement to convince a patient with 
severe hypertension but minimal symptoms that the treatment is worthwhile: 
he feels better without treatment. 
Almost all patients receiving ganglion blocking drugs are constipated, 
but most procure regular motions with Senokot or Petrolagar. A few 
develop an "all-or-none" bowel action. Without laxatives they are com-
pletely constipated yet the smallest effective dose of a mild purgative pro-
duces diarrhoea. Apart from the inconvenience involved, this hampers 
treatment; when constipated, more of the hypotensive drug is absorbed; when 
loose, part is lost in the motions. Smooth control of the arterial pressure 
becomes very difficult. 
Urine retention is an important side action in older men with benign 
prostatic hypertrophy. Secondary hypertensive disease in brain, myocardium 
or kidney may prevent surgical relief of the obstruction, whilst the danger 
of acute retention prevents treatment by ganglion blockade. 
Ganglion blockade may retard the progression of hypertensive renal 
disease but renal function is seldom improved. The reduction of renal blood 
flow has an adverse effect on impaired renal function. Further nitrogen 
retention may occur and renal. failure can develop. Patients with a blood 
urea nitrogen level over 60 mg. per 100 ml. usually deteriorate on ganglion 
blocking drugs. 
Other common side effects of ganglion blockade are blurred vision, dry 
mouth, reduced appetite and impotence. They seldom prevent continued 
therapy. The majority of the side effects are due to the interruption of 
transmission through parasympathetic ganglia. This prevents the normal 
functioning of the ciliary body, the salivary glands, the peristaltic reflex. 
the gastric and intestinal mucosae. the innervation of the bladder and the 
reflexes involved in erection and ejaculation. 
Attempts to produce specific sympathetic ganglion block have not been 
successful in spite of the anatomical and physiological differences between 
sympathetic and parasympathetic ganglia. There are, however. drugs which 
act specifically on post-ganglionic sympathetic nerves. 
4. Drugs which act on Sympathetic 3 R V W a * D Q J O L R Q L F  Nerves 
(a) RESERPINE. 
Plants of the genus Rauwolfia have been used for centuries in Africa 
and India chiefly in the treatment of insanity. Only in this century, however. 
have the Rauwolfia alkaloids become recognised as hypotensive agents. 
Three preparations from Rauwolfia are available; Raudixin is a powdered 
preparation of the whole root; Rauwiloid is a partially purified mixture of 
alkaloids: and reserpine is a pure crystalline alkaloid. the most important 
of the Rauwolfia group. 
Reserpine produces changes in behaviour: a treated animal lies quietly 
in its cage showing the minimum of spontaneous activity. It is inattentive 
and lacks concentration. Left alone it merely sleeps. Comparable doses 
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produce a similar effect in man. This sedation is different from that pro-
duced by the barbiturates. 
The cardiovascular effects of reserpine are bradycardia and a fall in 
arterial blood pressure. Other effects are increased gastro-intestinal motility. 
constriction of the pupil, relaxation of the nictitating membrane and loss 
of the pilo-erection response to cold. These effects develop very slowly, 
even after intravenous injection of the drug. Careful observation of animals 
soon after injection has revealed transient hyperglycaemia, pilo-erection, 
elevation of the arterial blood pressure and contraction of the denervated 
nictitating membrane. 
The mode of action of reserpine has been elucidated recently. In 1955 
Brodie and his eo-workers showed that reserpine liberates 5-0H tryptamine 
from brain and other tissues. Other pharmacologically active amines occur 
in brain, notably noradrenaline and adrenaline. Methods for their extrac-
tion, purification and assay have been developed by M. Vogt. They have 
a very similar distribution to 5-0H tryptamine, being found in the hypo-
thalamus, mid-brain and medulla. Recently it has been shown that these 
compounds are also liberated by reserpine. 
Sympathomimetic amines are also stored in adrenergic nerves and in 
the adrenal medulla. Following reserpine the concentration of these com-
pounds is reduced. In the cat, for example, reserpine reduces the nor-
adrenaline in the superior cervical ganglion from about 4.5 microgrammes 
per gramme to 1.5 or less. When the concentration falls below 1.0 micro-
gramme per gramme, peripheral transmission fails. Impulses pass through 
the ganglion but they fail to excite the effector structure. Apparently the 
quantity of noradrenaline released from the nerve terminals is reduced to 
an ineffective level. 
Reserpine appears to allow the sympathomimetic amines to leak out 
from cells into the plasma. A transient rise in the plasma adrenaline con-
centration after reserpine has been demonstrated in rabbits. This probably 
accounts for the transient hyperglycaemia, hypertension, pilo-erection and 
contraction of the denervated nictitating membrane. 
The repeated administration of therapeutic doses of reserpine to man is 
probably adequate to deplete the noradrenaline and adrenaline content of 
the sympathetic tissues: this has not yet been proved, however. Probably 
the hypotensive effect of reserpine is due to this. 
Reserpine is widely used in the treatment of hypertension. Some cases 
respond well to reserpine alone. The hypotensive action is moderate 
and they do not develop postural hypotension. Reserpine potentiates the 
blood pressure lowering effects of the ganglion blocking drugs without 
enhancing the undesirable side effects. 
The therapeutic ratio for reserpine is very much higher than for the 
veratrum alkaloids: nevertheless it has several side actions. Nasal con-
gestion, diarrhoea and dreams are the most common. The sedative effects 
are advantageous in over-active hypertensive patients. Some, however, 
experience severe depression. This is the most serious disadvantage of 
reserpine and often limits the use of the drug. A derivative with hypo-
tensive effects but no central depression would be valuable. 
(b) BRETYLIUM TOSYLATE (DARENTHIN). 
In 1957 Exley described a choline xylyl ether called T.M.IO; this 
compound is parasympathomimetic but has highly characteristic effects in 
addition. When a dose of 5-15 milligrammes per kilo is given intravenously 
to a cat peripheral sympathetic transmission is prevented. Impulses pass 
through the sympathetic ganglion and along the post-ganglionic sympathetic 
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nerve but the innervated organ is not excited. For example, stimulation 
of the cervical sympathetic chain no longer elicits a contraction of the 
nictitating membrane. Stimulation of the sympathetic nerves to the heart 
does not increase the heart rate, nor does stimulation of the sympathetic 
nerves to the salivary glands produce salivation. Each of these structures 
responds normally to adrenaline and noradrenaline however. The block 
in transmission appears to be at the adrenergic nerve ending. 
The properties of T.M.lO excited great interest and many structural 
analogues were prepared. The aim was to obtain a compound with the 
sympathetic blocking properties of T.M.IO but without the parasympatho-
mimetic effects. This aim has been realised in bretylium. 
Bretylium tosylate (Darenthin) is a simpler molecule than T.M.lO. The 
anion is p-toluene sulphonate but this is not necessary for pharmacological 
activity. 
Bretylium produces a specific sympathetic blockade; it lacks the para-
sympathomimetic effects of T.M.IO. Low doses which prevent the effects 
of sympathetic nerve stimulation do not prevent conduction along the nerve. 
They appear to stop the release of noradrenaline from the nerve ending. 
Large doses given over a long period do not deplete the noradrenaline 
stores, so that a reserpine-like action seems unlikely. 
Bretylium does not antagonise adrenaline or noradrenaline. On the con-
trary the treated animal becomes more sensitive to the sympathomimetic 
amines. The drug does not prevent the release of adrenaline from the 
adrenal medulla. It seems likely therefore that the influence of the adrenal 
on arterial blood pressure will be increased in patients treated with Bretylium. 
Bretylium is a quaternary ammonium ion and is not well absorbed from 
the alimentary tract. This is a disadvantage but it does not prevent oral 
administration. Following absorption the drug is selectively accumulated by 
adrenergic nerves. Carbon 14 labelled bretylium is found at these sites 
but not in the central nervous system. Urinary excretion is rapid and none 
of the drug can be detected in the urine after 24 hours. 
The cardiovascular effects of bretylium are similar to those of ganglion 
hlockade. In healthy young adults there is little change in supine blood 
pressure but the erect blood pressure is reduced. In hypertensive patients 
the supine pressures are lowered to a moderate extent but a much larger 
drop occurs when the patients stand erect. Postural hypotension occurs with 
large doses, especially after a heavy meal. Following oral ingestion the 
effects appear in about an hour. The maximum effect is seen after about 
three hours. 
Bretylium is undergoing clinical trial in many parts of the country. 
Suitable patients are those who have severe hypertension and would other-
wise be subjected to ganglion blockade. Tolerance develops to bretylium 
as it does to the ga!lglion blocking drugs but the undesirable side effects 
of the latter are not produced. Patients on bretylium do not complain of 
constipation, dry mouth, blurred vision and loss of appetite. Early experi-
ence suggests that bretylium will have the same effects as ganglion blocking 
drugs on impaired renal function. 
The development of a specific sympathetic blocking agent represents a 
major advance in the drug treatment of severe hypertension. Bretylium also 
provides the experimental pharmacologist with an exciting new tool. 
5. Drugs which act on Adrenergic Receptors 
Several peripheral antagonists of adrenaline and noradrenaline are known. 
They prevent access to adrenergic receptors. Some of them. like the ergot 
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alkaloids and tolazoline have additional actions which make them unsuit-
able for clinical use. Others, for example phentolamine (Rogitine), have 
an established place in the diagnosis of phaeochromocytoma. All the specific 
adrenaline antagonists are much more effective against adrenaline or nor-
adrenaline circulating in the blood than against noradrenaline released at 
nerve endings. They are ineffective in the treatment of essential hyper-
tension. 
6. Other Drugs 
In addition to the hypotensive agents described above, there are others 
which do not fit into the classification used. Hydralazine (Apresoline) is 
occasionally used in the treatment of patients with hypertension and impaired 
renal function. This drug is unique amongst the hypertensives in that it 
increases renal blood flow. However, the serious toxic effects of the drug 
restrict its use. 
Chlorothiazide (Saluric) is a potent oral diuretic. Where hypertension 
is associated with fluid retention as in pre-eclampsia, patients often respond 
to this drug with a copious diuresis and a fall in arterial blood pressure. 
& K O R U R W K L D ] L G H  has also been shown to potentiate the effects of the hypo-
tensive drugs. The dose of a ganglion blocking drug required for a given 
depression of the arterial blood pressure may be reduced by half. The 
mode of potentiation is not clear. 
The peripheral vasodilator drugs, for example glycerol trinitrate and 
amyl nitrite, reduce peripheral resistance and lower blood pressure. The 
effect is variable and transient however, and a reflex tachycardia is pro-
duced. They are not suitable for the sustained lowering of blood pressure 
in hypertensive patients. 
Summary 
1. The arterial blood pressure in the patient with early essential hyper-
tension is regulated by the carotid sinus reflexes. Many of the drugs 
which lower arterial blood pressure interfere with the reflex 
mechanism. 
2. Several drugs which lower arterial pressure by actions on the sensory 
and central parts of the reflex pathway are described. The cardio-
vascular effects of ganglion blocking agents are outlined; attention 
is drawn to the desirability of specific sympathetic blockade. 
3. Recent work on reserpine is described and the need for a similar 
drug without depressive effects is emphasised. The recently intro-
duced specific sympathetic blocking agents are of great theoretical 
and practical interest. Several other hypotensive agents are given 
brief mention. 
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